Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Market & Forensics Analyst

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

<ul>
<li>India’s planned BESS requirement rises from 24 GWh in FY27 to 321 GWh by FY36, while nearly 99 GWh is already under construction or tender.</li>
<li>The opportunity is moving upstream: salts, electrolyte, additives, cathode, anode and binders are the strategic bottlenecks, not merely cell assembly.</li>
<li>GFL, Neogen, Himadri and Acutaas offer the clearest Li-ion exposure; Balaji and Aether are optionality; Tatva is primarily a supercapacitor/zinc-storage play.</li>
</ul>


India’s planned BESS requirement rises from 24 GWh in FY27 to 321 GWh by FY36, while nearly 99 GWh is already under construction or tender.
The opportunity is moving upstream: salts, electrolyte, additives, cathode, anode and binders are the strategic bottlenecks, not merely cell assembly.
GFL, Neogen, Himadri and Acutaas offer the clearest Li-ion exposure; Balaji and Aether are optionality; Tatva is primarily a supercapacitor/zinc-storage play.


India’s Battery-Chemicals Buildout: The Proxy Trade of BESS Gigafactories

India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

<ul>
<li>
Global chemical inventory levels are at decade lows, and product prices have begun stabilizing across key segments, signaling the early stages of a demand-led recovery. </li>
<li>The capex cycle is largely behind us, setting the stage for strong free cash flow generation even as select sub-segments like amines, fluorine, and pyridines see pricing and volume tailwinds. 
</li>
<li>We adopt a selective bullish view, with momentum expected in companies that have strategically aligned capex, strong product-market fit, and established global customer relationships. 
</li>
</ul>



Global chemical inventory levels are at decade lows, and product prices have begun stabilizing across key segments, signaling the early stages of a demand-led recovery. 
The capex cycle is largely behind us, setting the stage for strong free cash flow generation even as select sub-segments like amines, fluorine, and pyridines see pricing and volume tailwinds. 

We adopt a selective bullish view, with momentum expected in companies that have strategically aligned capex, strong product-market fit, and established global customer relationships. 



Thematic Report on What’s Different About the Chemical Recovery This Time?

Equity Bottom-Up

<ul>
<li>A two-week US-Iran-Israel ceasefire took effect on April 8, reopening the Strait of Hormuz after 39 days of conflict that destroyed 85% of Iran's petrochemical output.</li>
<li>With Iranian methanol, ammonia, and urea capacity offline for 6 to 9 months minimum, Indian producers across 7 chemical sub-sectors inherit a structural margin window in Q1 FY27.</li>
<li>The ceasefire removes the supply-chain shock but not the production gap: infrastructure damage at Mahshahr and Asaluyeh will take years to rebuild, making India's import substitution plays more durable.</li>
</ul>


A two-week US-Iran-Israel ceasefire took effect on April 8, reopening the Strait of Hormuz after 39 days of conflict that destroyed 85% of Iran's petrochemical output.
With Iranian methanol, ammonia, and urea capacity offline for 6 to 9 months minimum, Indian producers across 7 chemical sub-sectors inherit a structural margin window in Q1 FY27.
The ceasefire removes the supply-chain shock but not the production gap: infrastructure damage at Mahshahr and Asaluyeh will take years to rebuild, making India's import substitution plays more durable.


India's Chemical and Fertilizer Winners from the Middle East Ceasefire

APAC IPOs & Placements, Aequitas Research

Akshat Shah

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Anthem Biosciences / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/anthem-biosciences" target="_blank" data-smartkarma-citation="entities:44206:1" rel="noopener">Anthem Biosciences (1234D IN)</a> is looking to raise up to US$400m in its upcoming India IPO.</li>
<li>Anthem Biosciences (ABS) is a contract research, development and manufacturing organisation (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing.</li>
<li>In this note, we talk about the not-so-positive aspects of the deal.</li>
</ul>



Anthem Biosciences (1234D IN) is looking to raise up to US$400m in its upcoming India IPO.
Anthem Biosciences (ABS) is a contract research, development and manufacturing organisation (CRDMO) with fully integrated operations spanning drug discovery, development, and manufacturing.
In this note, we talk about the not-so-positive aspects of the deal.


Anthem Biosciences Pre-IPO - The Negatives- Margins Aren't There Yet

Shiva Pharmachem Limited / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shiva-pharmachem-limited" target="_blank" data-smartkarma-citation="entities:40109:1" rel="noopener">Shiva Pharmachem Limited (9155347Z IN)</a> is looking to raise around US$110m in its India IPO.</li>
<li>It is a manufacturer in the Indian specialty chemicals business and was the largest manufacturer of acid and alkyl chlorides by volume in CY22 in India, as per Frost&amp;Sullivan .</li>
<li>In this note, we talk about the company’s historical performance.</li>
</ul>



Shiva Pharmachem Limited (9155347Z IN) is looking to raise around US$110m in its India IPO.
It is a manufacturer in the Indian specialty chemicals business and was the largest manufacturer of acid and alkyl chlorides by volume in CY22 in India, as per Frost&amp;Sullivan .
In this note, we talk about the company’s historical performance.


Shiva Pharmachem Pre-IPO - High Borrowings Along with Expansion Plans Leading to Liquidity Concerns

India

Balaji Amines Limited is a leading Indian manufacturer specializing in aliphatic amines, their derivatives, and specialty fine chemicals, providing essential raw materials for pharmaceuticals, agrochemicals, and other specialized sectors. The company is a key player in the chemical industry, developing indigenous manufacturing technologies to reduce import dependency. It was established in 1988 and is headquartered in Solapur, Maharashtra, India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Balaji Amines (BLA IN)

India’s Battery-Chemicals Buildout: The Proxy Trade of BESS Gigafactories

India's demand for battery energy storage systems is rapidly increasing, with strategic bottlenecks shifting towards materials and components...

Nimish Maheshwari

Thematic Report on What’s Different About the Chemical Recovery This Time?

Global chemical inventory levels are at decade lows, signaling the early stages of a demand-led recovery. Selective bullish view on companies with...

Sudarshan Bhandari

India's Chemical and Fertilizer Winners from the Middle East Ceasefire

Ceasefire in US-Iran-Israel conflict reopens Strait of Hormuz, but Indian chemical producers benefit from Iran's production setback.

Nimish Maheshwari

Anthem Biosciences Pre-IPO - The Negatives- Margins Aren't There Yet

Anthem Biosciences is looking to raise up to US$400m in its upcoming India IPO. In this note, we talk about the not-so-positive aspects of the deal.

Akshat Shah

Shiva Pharmachem Pre-IPO - High Borrowings Along with Expansion Plans Leading to Liquidity Concerns

Shiva PharmaChem is looking to raise around US$110m in its India IPO. In this note, we talk about the company’s historical performance.

Akshat Shah

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

India’s Battery-Chemicals Buildout: The Proxy Trade of BESS Gigafactories

​India's demand for battery energy storage systems is rapidly increasing, with strategic bottlenecks shifting towards materials and components...

Nimish Maheshwari

Thematic Report on What’s Different About the Chemical Recovery This Time?

​Global chemical inventory levels are at decade lows, signaling the early stages of a demand-led recovery. Selective bullish view on companies with...

Sudarshan Bhandari

India's Chemical and Fertilizer Winners from the Middle East Ceasefire

​Ceasefire in US-Iran-Israel conflict reopens Strait of Hormuz, but Indian chemical producers benefit from Iran's production setback.

Nimish Maheshwari

Anthem Biosciences Pre-IPO - The Negatives- Margins Aren't There Yet

Anthem Biosciences is looking to raise up to US$400m in its upcoming India IPO. In this note, we talk about the not-so-positive aspects of the deal.

Akshat Shah

Shiva Pharmachem Pre-IPO - High Borrowings Along with Expansion Plans Leading to Liquidity Concerns

Shiva PharmaChem is looking to raise around US$110m in its India IPO. In this note, we talk about the company’s historical performance.

Akshat Shah

India's demand for battery energy storage systems is rapidly increasing, with strategic bottlenecks shifting towards materials and components...

Global chemical inventory levels are at decade lows, signaling the early stages of a demand-led recovery. Selective bullish view on companies with...

Ceasefire in US-Iran-Israel conflict reopens Strait of Hormuz, but Indian chemical producers benefit from Iran's production setback.